Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-710-1
CAS number: -
of CJ302 in rat’s maternal toxicity, or teratogenic and
embyo-/fetotoxicity performance was 1000 mg/kg/day (OECD TG414).
using the procedures outlined in the SYRICI Study
Plan for G1863B0030 and OECD 414. There were thirty or thirty-one mated
female rats in each group, which resulted in 31, 29, 26 and 27 pregnant
rats in vehicle control group and the low-, mid- and high-,
respectively. CJ302 (100, 300 or 1000 mg/kg.d.) was given orally by
gavage daily during the day 5~19 of pregnancy (GD5~19), and were
euthanized with CO2 on GD20.
or treatment-related clinical toxicity were observed in the course of
this study. Most of rats in the mid- and high-dose groups had red faeces
after being administrated, but which was considered to be caused with
the color of CJ302 and without adverse effect. During the administration
period, the mean body weights and body weight change of pregnant rats in
all dosed groups had no statistically significant difference compared
with the control group. At the same time, no significant effect in food
aonsumption of the pregnant rat during the treated period was observed
in all dose groups. In all dose groups, no adverse effect was observed
in all prenatal reproductive parameters.
examination showed that no adverse effect in body weight and sex
distribution of live fetuses was observed in all dosed group. No adverse
effect attribution to treatment was observed across all groups with
respect to examined, soft-tissue and skeletal malformations or
variations except that some examined fetuses had less than six sternal
ossification points, but there was no difference in the mean number of
sternal ossification points in all dosed groups as compared with the
the no observed adverse effect levelof
CJ302 in rat’s maternal toxicity, or teratogenic and embyo-/fetotoxicity
performance was 1000 mg/kg.d.
on developmental toxicity: via oral route
thirty or thirty-one mated female rats in each group, which resulted in
31, 29, 26 and 27 pregnant rats in vehicle control group and the low-,
mid- and high-, respectively. CJ302 (100, 300 or 1000 mg/kg.d.) was
given orally by gavage daily during the day 5~19 of pregnancy (GD5~19),
and were euthanized with CO2 on GD20.
the no observed adverse effect level of CJ302 in rat’s maternal
toxicity, or teratogenic and embyo-/fetotoxicity performance was 1000
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again